Seelos Therapeutics' ALS treatment fails in mid-stage study (updated)

Seelos Therapeutics

19/03/2024 12:43

(Adds share movement in paragraph 2, details in paragraphs 3 &
4)
       March 19 (Reuters) - Seelos Therapeutics'  SEEL.O 
experimental drug for a neurological disorder called ALS, or
amyotrophic lateral sclerosis, failed to meet the main goal in a
mid-stage trial, the company said on Tuesday.
    Shares of the company plunged 51% to 44 cents in trading
before the bell.
    The drug, SLS-005, did not show statistical significance in
improving function and mortality during the trial.
    ALS is a rare disease that can affect nerve cells in the
brain and spinal cord responsible for muscle movements, leading
to progressive paralysis and death.

 (Reporting by Christy Santhosh; Editing by Savio D'Souza and
Shailesh Kuber)
 ((Christy.Santhosh@thomsonreuters.com;))